CD68/CD163 Mark Worse Outcomes in Skeletal Hodgkin Lymphoma, Study
-
By
August 28, 2025
-
3 min
-
1
Skeletal Hodgkin lymphoma has a macrophage-rich microenvironment.
-
2
High CD68 expression is linked to poorer outcomes.
-
3
Chemotherapy regimen studied was ABVD.
-
4
578 genes were analyzed showing differential expression.
-
5
Skeletal involvement correlates with worse overall survival.
-
6
High CD206 is associated with superior progression-free survival but poorer overall survival.
-
Recent research shows skeletal classic Hodgkin lymphoma is characterized by a macrophage-rich and B-cell-poor tumor microenvironment, which correlates with worse overall survival among patients treated with a combination of chemotherapy agents. A comparison of patients with skeletal disease against those with nodal-only disease revealed distinct gene expression profiles, with higher macrophage markers like CD68 and CD163 and lower B-cell markers such as CD20. The study found that skeletal involvement significantly impacts overall survival, suggesting macrophage markers may guide treatment strategies.
-
1
Skeletal Hodgkin lymphoma has a macrophage-rich microenvironment.
-
2
High CD68 expression is linked to poorer outcomes.
-
3
Chemotherapy regimen studied was ABVD.
-
4
578 genes were analyzed showing differential expression.
-
5
Skeletal involvement correlates with worse overall survival.
-
6
High CD206 is associated with superior progression-free survival but poorer overall survival.
Listen Tab content
